Structure-based drug design identifies novel LPA3 antagonists.
about
Structural Characterization of an LPA1 Second Extracellular Loop Mimetic with a Self-Assembling Coiled-Coil Folding ConstraintPharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.2D binary QSAR modeling of LPA3 receptor antagonism.Aiming drug discovery at lysophosphatidic acid targets.Lysophosphatidic acid-1-receptor targeting agents for fibrosis.Design of anticancer lysophosphatidic acid agonists and antagonists.
P2860
Structure-based drug design identifies novel LPA3 antagonists.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Structure-based drug design identifies novel LPA3 antagonists.
@en
Structure-based drug design identifies novel LPA3 antagonists.
@nl
type
label
Structure-based drug design identifies novel LPA3 antagonists.
@en
Structure-based drug design identifies novel LPA3 antagonists.
@nl
prefLabel
Structure-based drug design identifies novel LPA3 antagonists.
@en
Structure-based drug design identifies novel LPA3 antagonists.
@nl
P2093
P2860
P1476
Structure-based drug design identifies novel LPA3 antagonists.
@en
P2093
Abby L Parrill
Gabor Tigyi
James I Fells
Jianxiong Liu
Ryoko Tsukahara
P2860
P304
P356
10.1016/J.BMC.2009.09.022
P407
P577
2009-09-18T00:00:00Z